A Study of JNJ-56136379 in Healthy Participants

NCT04853524 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

Healthy

Interventions

DRUG: JNJ-56136379
DRUG: Bictegravir (BIC) plus Emtricitabine (FTC) plus Tenofovir Alafenamide (TAF)

Sponsor

Janssen Research & Development, LLC